Aldose Reductase Deficiency Protects from Autoimmune- and Endotoxin-Induced Uveitis in Mice

Umesh C. S. Yadav, Mohammed Shoeb, Satish K. Srivastava, and Kota V. Ramana

**Purpose.** To investigate the effect of aldose reductase (AR) deficiency in protecting the chronic experimental autoimmune uveitis (EAU) and acute endotoxin-induced uveitis (EIU) in c57BL/6 mice.

**Methods.** The WT and AR-null (ARKO) mice were immunized with human interphotoreceptor retinoid-binding peptide (hIRPB-1–20), to induce EAU, or were injected subcutaneously with lipopolysaccharide (LPS; 100 μg) to induce EIU. The mice were killed on day 21 for EAU and at 24 hours for EIU, when the disease was at its peak, and the eyes were immediately enucleated for histologic and biochemical studies. Spleen-derived T-lymphocytes were used to study the antigen-specific immune response in vitro and in vivo.

**Results.** In WT-EAU mice, severe damage to the retinal wall, especially to the photoreceptor layer was observed, corresponding to a pathologic score of ~2, which was significantly prevented in the ARKO or AR inhibitor–treated mice. The levels of cytokines and chemokines increased markedly in the whole-eye homogenates of WT-EAU mice, but not in ARKO-EAU mice. Further, expression of inflammatory marker proteins such as inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, tumor necrosis factor (TNF)-α, and vascular cell adhesion molecule (VCAM)-1 was increased in the WT-EIU mouse eyes but not in the ARKO-EIU eyes. The T cells proliferated vigorously when exposed to the hIRPB antigen in vitro and secreted various cytokines and chemokines, which were significantly inhibited in the T cells isolated from the ARKO mice.

**Conclusions.** These findings suggest that AR-deficiency/inhibition protects against acute as well as chronic forms of ocular inflammatory complications such as uveitis. (Invest Ophthalmol Vis Sci. 2011;52:8076–8085) DOI:10.1167/iovs.11-7830

Uveitis, a common cause of vision loss, accounts for 5% to 15% of all cases of blindness worldwide affecting individuals of all ages, both sexes, and all races.1 In the United States, a total of 150,000 cases of uveitis are reported annually, and approximately 10% result in severe visual handicaps.2 In most of the patients, the etiology is difficult to define, as the causes could vary from infections, trauma, and autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, polyarthritis nodosa, relapsing polychondritis, Wegener’s granulomatosis, Behçet’s disease, Reiter’s disease, Crohn’s disease, and ankylosing spondylitis.3–7 Although there is no appropriate animal model for the study of such a varied pathophysiology in humans, the closest to endogenous uveitis in humans are the acute form of bacterial endotoxin, lipopolysaccharide (LPS)-induced uveitis, and experimental autoimmune uveitis (EAU) induced in mice by immunization with retinal antigenic peptides.8–10 Various investigators have suggested the use of these animal models to study the efficacy of pharmacologic inhibitors in patients.11,12

In the past few years, aldose reductase (AR), a rate-limiting enzyme of the polyol pathway that reduces glucose into sorbitol in the presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH), has emerged as the molecular target that mediates various inflammatory diseases.13,14–17 We have shown that AR mediates the pathogenesis of endotoxin-induced uveitis (EIU) in rats, and its inhibition could be beneficial in the treatment of acute uveitis.16 Since the pathophysiology of endogenous uveitis differs from that of the exogenous form, particularly injection-induced uveitis, and involves the participation and activation of Th1 lymphocytes, we have investigated whether genetic deficiency or inhibition of AR could be protective against disease development in a mouse model of uveitis. We have also tested the efficacy of fidaestat, a highly specific inhibitor of AR, against both forms of uveitis. Fidaestat was used because it has already undergone a phase III clinical trial for diabetic neuropathy and was found to be safe for human use.17

Besides the different mechanism in the pathophysiology, the common denominator in both types of uveitis is the inflammation that stems from the oxidative stress caused by different stimuli.18–22 The oxidative stress is generated in the endotoxin-induced uveitis by the bacterial cell wall component, LPS, which is known to activate NADPH oxidases (NOX).23,24 Further, in autoimmune uveitis, oxidative stress emanates from the ongoing systemic chronic inflammation in the body which activates the circulating leukocytes. The activated leukocytes cross the blood–retinal barrier and generate more ROS, thereby severely damaging the photoreceptor layer in the retinal wall and exacerbating the pathophysiology of endogenous uveitis.25,26 Several investigators have demonstrated that oxidative stress-induced inflammatory process is one of the key contributing factors in the pathophysiology of uveitis.13,20,27 Therefore, containing the oxidative stress–induced molecular signals that transcribe inflammatory cytokines, chemokines, and other mediators could suppress the inflammation and ameliorate the potentially sight-threatening pathology. Since we and others have demonstrated previously that AR inhibition blocks the molecular signals initiated by oxidative stress and thus prevents several pathologic conditions, including diabetic, cardiovascular, sepsis, cancer, and allergy in animal models,28–35 we postulate that pharmacological inhibition or genetic silencing of this enzyme could offer a potential opportunity to treat both acute and chronic forms of ocular inflammation in uveitis. Therefore, we investigated the...
effect of AR deficiency as well as the efficacy of the AR inhibitor fidaestat in the prevention of both chronic (i.e., experimental autoimmune uveitis [EAU]) and acute endotoxin-induced uveitis (EIU) in mice. Our results showed that AR deficiency prevented the inflammatory changes in mouse eyes associated with EAU and EIU induced by immunization with hIRBP and injection of the bacterial endotoxin LPS, respectively. These findings suggest that AR inhibition could be used in the treatment of ocular inflammatory complications such as uveitis.

**Materials and Methods**

**Materials**

Human IRBP-derived peptide 1-20 (H2N-GPTHLFQPSLVLDMAKVLLD-H9262) was synthesized and purified by CHI-Scientific (Maynard, MA). Complete Freund’s adjuvant (CFA) was purchased from Sigma-Aldrich (St. Louis, MO). Purified Bordetella pertussis toxin (PTX) was from Calbiochem (San Diego, CA). Mycobacterium tuberculosis H37RA was purchased from Difco Laboratories (Detroit, MA). RPMI-1640 medium, phosphate-buffered saline (PBS), gentamicin sulfate solution, penicillin and streptomycin, trypsin/EDTA (EDTA) solution, and fetal bovine serum (FBS) were purchased from Invitrogen-Gibco (Grand Island, NY). Fidarestat was obtained as a gift from Sanwa Kagaku Kenkusho Co. Ltd. (Nagoya, Japan). Dimethyl sulfoxide (DMSO) was obtained from Fisher Scientific (Pittsburgh, PA). Antibodies against iNOS, COX-2, and VCAM-1 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and TNF-α antibodies were purchased from Abcam (Cambridge, MA). A membrane-based cytokine array system was purchased from RayBiotech, Inc. (Norcross GA). All other reagents used were of analytical grade.

**Animals**

Approximately 8-week-old C57BL/6 mice were obtained from Harlan Laboratories (Indianapolis, IN), and AR-knockout (ARKO) mice were bred and maintained in a pathogen-free condition in the animal resource center under the 12-hour light and dark cycles, at University of Texas Medical Branch at Galveston, where food and water were provided ad libitum. All studies were conducted in compliance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

**Induction of EAU and EIU**

To induce experimental autoimmune uveitis, the mice were immunized by subcutaneous (SC) injections into both hind thighs with 100 μg of hIRBP in 100 μL of emulsion with CFA (1:1, vol/vol), which was supplemented with 2.5 mg/mL of heat-killed M. tuberculosis H37Ra (Difco Laboratories). Concurrently, an intraperitoneal (IP) injection containing 0.5 μg purified B. pertussis toxin (PTX; Calbiochem) in 100 μL phosphate-buffered saline (PBS) was also administered as an additional adjuvant. For the induction of adoptively transferred uveitis, T cells were isolated from spleen (as described below) of wild-type (WT) and ARKO mice immunized with hIRBP-20 on day 12 after immunization and cultured with 20 μg/mL of IRBP1-20, along with gamma-irradiated (2500 rad) syngeneic spleen cells as APCs for 3 days. The activated T cells were separated on a single-density gradient (Ficoll; GE Healthcare, Piscataway, NJ) and 5 × 10⁶ cells suspended in 0.2 mL of PBS were injected per mouse, such that activated T cells from WT mice were injected into WT as well as ARKO mice and that from ARKO mice were injected in WT as well as ARKO mice. The disease severity and histopathologic assessments were performed on day 14 after transfer. EIU was induced in mice by giving SC injection of LPS (100 μg) dissolved in PBS.

**AR Inhibitor Treatment**

For the treatment of EAU mice from the second day onward, the mice were injected (IP) with the AR inhibitor fidaestat (7 mg/kg/d) in a volume of 25 μL DMSO daily. At this dose, fidaestat significantly inhibited the AR activity (data not shown). The control mice received an equivalent amount of the carrier. For EIU experiments, the mice were treated with the inhibitor 1 day and 2 hours before LPS injection.

To examine the therapeutic efficacy of fidaestat, the inhibitor was administered starting on day 12 in drinking water ad libitum, such that they received approximately 150 μg per mouse per day (determined by us based on average water consumption per mouse per day).

**Pathologic Assessment of Uveitis in Mice**

The severity of EAU and inflammation was scored on a scale of 0 to 4 by slit lamp biomicroscopic examination by an expert ophthalmologist who was blinded to the experimental groups. The scale was as follows: grade 0, no disease, with eyes translucent and reflecting light (red reflex); grade 1, enlargement of the iris vessel and abnormal pupil contraction; grade 2, cellular infiltrates and hazy anterior chamber, with a decreased red reflex; grade 3, a moderately opaque anterior chamber, with the pupil still visible and a dull red reflex; and grade 4, an opaque anterior chamber, obscured pupil, and absence of red reflex.56

**Histology**

The mice were killed on day 21, when maximum disease activity was reported. The eyes were enucleated and either quickly frozen for biochemical determinations later or fixed in special solution for 24 hours, followed by dehydration, paraffin embedding, and sectioning (5 μm) for histopathologic examination, after staining with hematoxylin and eosin (H&E). For histopathologic evaluation, the iris-ciliary body complex, anterior chamber, vitreous, and retina were observed under light microscope. The spleens were harvested immediately and used for the separation of T cells which were used in the antigen-induced cell-viability assay and for the determination of levels of inflammatory cytokines and chemokines, as described below.

**Immunohistochemical Studies**

The paraffin-embedded sections were deparaffinized by warming at 60°C for 1 hour and incubation in xylene three times for 10 minutes each followed by rehydration by passing through 100%, 95%, 80%, and 70% ethanol and finally deionized water. The sections were rinsed in PBS two times for 5 minutes each and incubated with blocking buffer (2% BSA, 0.1% Triton X-100, 2% normal rabbit IgG, and 2% normal goat serum) overnight at 4°C. They were then incubated with antibodies against iNOS (1:250 dilution), COX-2 (1:300 dilution) overnight at 4°C. The sections were incubated with fluorescein isothiocyanate (FITC)-labeled secondary antibodies. The slides were mounted with mounting medium containing fluorescent 4′,6-diamidino-2-phenylindole (DAPI; Vectashield; Vector Laboratories, Burlingame, CA) and examined under a fluorescence (using FITC filters) microscope (EPI-800 microscope; Nikon, Tokyo, Japan) and photographed with a digital camera fitted to the microscope.

**T-Cell Viability Assay Using the MTS Assay**

The T-cell viability assay in response to the antigen (hIRBP peptide) was performed with spleen-derived T lymphocytes. The splenocytes were obtained from mouse spleens (gentleMACS Dissociator; Miltenyi Biotec, Auburn, CA), and T-cell-enriched fractions were prepared by passing the dispersed splenocytes over nylon-wool columns. Nylon-wool nonadherent cells (2 × 10⁶/well) were cultured in quadruplicate with gamma-irradiated (2500 rad) syngeneic spleen cells and 20 μg of peptide in a 96-well flat-bottomed microtiter plate for 72 hours at 37°C. The T-cell viability measured by a nonradioactive cell-proliferation assay using MTS dye (CellTiter 96 AQueous; Promega; Madison, WI), composed of solutions of tetrazolium compound (5(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-2H-tetrazolium). At the end of incubation, the MTS dye was added in the wells and incubated for an additional 3 hours, and the plates were read at 490 nm.
with a multiwell ELISA plate reader. The absorbance represented T-cell growth in response to antigen, and the data are presented as the mean absorbance ± SD.

**Determination of IL-17 Levels in T-Cell Culture Media**

To assess the antigen-specific immune response of T-lymphocytes in vitro, IL-17 cytokine produced in the T-cell culture supernatant was quantified. The spleen-derived T cells (5 × 10⁵/well) were cultured with 20 μg hIRBP in the absence or presence of fidarestat (10 μM; dissolved in water) for 72 hours. The control cells received equivalent volumes of carrier. At the end of incubation, the culture media were harvested, cleared by centrifugation (5000 rpm; 5 minutes), and stored at −80°C until used for the IL-17 determinations using a mouse cytokine antibody array system, according to the manufacturer’s instructions (Cosmo Bio, Carlsbad, CA).

**Determination of Inflammatory Cytokines Levels in T-Cell Culture Media and Whole Eye Lysate**

The T-cell media were obtained, as described above, and whole-eye lysates were prepared by homogenizing the eyeballs in RIPA lysis buffer, containing protease inhibitor cocktail. Inflammatory cytokines and the chemokine profile in T-cell culture media and whole-eye homogenates were determined with a mouse cytokine antibody array system (RayBio, Norcross, GA) that determines the expression of 64 inflammatory markers from a single sample, according to the manufacturer’s instructions. The culture media and tissue homogenates were incubated with an antibody array support membrane; the membrane was specifically coated with various antigens to capture an array of cytokines and chemokines. The tagged proteins were detected by conjugation with biotinylated antibodies and a streptavidin system. The fold change was calculated from the measured intensities of the individual spots signal developed on x-ray film using densitometry software (Eastman Kodak, Rochester, NY).

**Western Blot Analysis**

The whole-eye lysate was prepared by homogenizing the eyeballs in ice-cold RIPA lysis buffer containing 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 1:100 dilutions of protease inhibitor and phosphatase inhibitor cocktails (Sigma-Aldrich) on ice. The whole-eye lysates were cleared by centrifugation at 12,000g for 10 minutes at 4°C. The amount of protein in the lysates was determined using the Bradford reagent (Bio-Rad Laboratories, Hercules, CA). Western blot analysis was performed as described by us elsewhere, using antibodies against the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to assess the equal loading of proteins. The data are presented as the mean ± SD, and P values were determined by unpaired Student’s t-test. For animal studies, data collected from in vitro and in vivo experiments were analyzed by ANOVA, followed by Bonferroni post hoc analyses for least significant difference, and P < 0.05 was considered statistically significant.

**Results**

**Histopathology of EAU**

We determined the effect of AR deficiency on the pathophysiology of EAU by examining the clinical score of the disease on day 21 when the disease was at its peak. As shown in Figure 1A, the WT mice with EAU had a significantly high (P < 0.001) pathologic score of 3.12 ± 0.41 on the scale of 4 and the ARKO mice had an average score of 1.38 ± 0.48 which was significantly (P < 0.02) less than the pathologic score in the WT EAU mice. When histopathologic symptoms of the two groups were compared, the sections of the WT EAU eyes showed inflammatory cell infiltration in the posterior as well as anterior chambers, accompanied with the blebbing and extensive damage of the photoreceptor layer in the retina (Fig. 1B). These changes were markedly absent in the ARKO mice, except that in one third of the mice with EAU, mild cellular infiltration, retinal edema, and damage to photoreceptor layers were observed, suggesting that the deficiency of AR protected the development of EAU on immunization with the antigen.

**Adoptive Transfer of Antigen-Activated T Cells Derived from AR-Null Mice Does Not Induce EAU**

Next, we examined the effect of AR deficiency on the EAU caused by adoptive transfer of activated T cells where CD4⁺ T cells were isolated from the hIRBP-immunized WT and ARKO
observed in either the WT or the ARKO mice (Fig. 2). These results indicate that protection offered by AR deficiency is most likely due to nonactivation and lack of expansion of the pathologic subsets of T cells.

**Viability of Spleen-Derived T Cells after Stimulation with hIRBP**

To confirm whether protection by AR deficiency is due to nonactivation and lack of expansion of the pathologic T-cell subset, we next measured the viability of spleen-derived T cells in response to antigen hIRBP. We isolated T cells from mouse spleen and purified them over nylon-wool columns and, as determined by fluorescence-activated cell sorting (FACS) analysis, the T-cell population was more than 95% pure (data not shown). The WT EAU mouse-derived T-cell population increased more than twofold compared with T cells derived from WT control mice when incubated for 72 hours in the culture media alone and further increased to more than fourfold in the presence of antigen. On the other hand, the viability of T cells from the ARKO EAU mice was significantly lower, approximately 50% less in the absence of antigen and more than 85% less when the antigen was present in the culture medium compared with WT EAU (Fig. 3). T cells derived from the control did not grow in the absence or the presence of antigen. These results suggest that AR regulates the antigen-induced growth of primed T cells and its absence was crucial in slowing the viability of spleen-derived T cells.

**Expression of the Inflammatory Markers iNOS and COX-2 during EAU**

Next, we immunostained the eye sections with antibodies for the inflammatory marker iNOS and COX-2, which are well-known participants in the inflammation during uveitis. As shown in Figure 4A, there was a marked increase in the expression of iNOS in the cells of the retinal wall in the WT mice with EAU, whereas in the ARKO mouse eyes with EAU, iNOS-specific staining was minimal. Similarly, COX-2 expression increased in the retina at day 21 of immunization in the WT mice, as determined by increased fluorescence, whereas in the ARKO mice, the expression was comparatively less and was similar to that in the control mice (Fig. 4B). These
results suggest that EAU-related expression of inflammatory marker proteins was markedly decreased in the ARKO mice.

**Inflammatory Cytokine and Chemokine Secretion by Spleen-Derived T Cells after Stimulation with hIRBP**

To further assess the role of T cells in inflammation during EAU, we determined the inflammatory markers secreted by T cells in the medium when stimulated with the antigen. As shown in Table 1, the culture media from the WT EAU mouse-derived T cells incubated with hIRBP showed severalfold increased expression of cytokines (such as IL-1α, IL-1β, IL-6, IFN-γ, TNF-α, and IL10) and chemokines (CINC-3, CNTF, Fractalkine, MIP-3α, and MCP1) when stimulated with the antigen, and their levels were comparatively low in the ARKO mice, suggesting that AR deficiency resulted in lower expression of inflammatory markers when challenged with the antigen. The levels of inflammatory markers remained at the basal level (no significant change) in the media of the WT and ARKO-derived T cells with no antigen challenge.

**Secretion of IL-17 by Spleen-Derived T Cells after Stimulation with hIRBP**

Since IL-17 has been implicated in the pathogenesis of EAU, we next measured the levels of IL-17 in the T-cell culture media 72 hours after hIRBP challenge. As shown in Figure 5, the T-cell media from the control animals had only a basal level of IL-17, as did the media from unchallenged T cells from the EAU WT and ARKO mice. When challenged with hIRBP, the levels of IL-17 increased significantly to 424 pg/mL in the EAU-derived T-cell media which was approximately 20 pg/mL without hIRBP challenge and was 203 pg/mL (~50% less compared with the WT EAU) in the ARKO group treated with hIRBP. These results suggest that IL-17 is elevated in T-cell culture medium, a subpopulation of Th-17

**Table 1. Expression of Inflammatory Markers in Culture Media from EAU Mouse-Derived T Cells Incubated with hIRBP**

<table>
<thead>
<tr>
<th>Growth Factors, Cytokines, Chemokines</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WT-EAU vs. ARKO-EAU</strong></td>
<td></td>
</tr>
<tr>
<td>CINC-3, CNTF, Fractalkine, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-6, IL-10, Leptin, MCP-1, MIP-3α, β-NGF, TIMP-1, TNF-α, VEGF</td>
<td>0–1</td>
</tr>
<tr>
<td><strong>WT-EAU vs. WT-EAU+IRBP</strong></td>
<td></td>
</tr>
<tr>
<td>CINC-3, CNTF, Fractalkine, IL-6, MIP-3α, IFN-γ, IL-1α, IL-1β, IL-10, Leptin, GM-CSF, β-NGF, TNF-α, VEGF</td>
<td>2–5</td>
</tr>
<tr>
<td>TIMP-1, MCP-1</td>
<td>1–3</td>
</tr>
<tr>
<td><strong>AR KO-EAU+IRBP vs. WT-EAU+IRBP</strong></td>
<td></td>
</tr>
<tr>
<td>CINC-3, Fractalkine, IL-4, IL-6, IL-10, CINC-2, CNTF, IFN-γ, IL-1α, IL-1β, LIX, Leptin, MIP-3α, β-NGF, MCP-1, TIMP-1, TNF-α, VEGF</td>
<td>0–1</td>
</tr>
</tbody>
</table>

AR deficiency prevented an hIRBP-induced increase in cytokines, chemokines, and growth factors in spleen-derived T-cell culture media. A membrane-based cytokine antibody array system was used to determine the expression levels of the inflammatory factors in the T-cell media. The spots on the array-membrane were analyzed by densitometry and the data are presented as fold change in expression. The WT-EAU and ARKO EAU T-cell media served as the controls (n = 4).
cells differentiate in the spleen-derived T cells when challenged with antigen, and AR plays a critical role in this process.

**AR Inhibition by Fidarestat Prevents Pathogenesis of EAU in Mouse Eyes**

Next, we used a specific AR inhibitor, fidarestat, and examined the pathogenesis of EAU. As shown in Figure 6A, the clinical EAU score of 3 in the WT mice was decreased by ~50% when the mice were treated with fidarestat. Further, when fidarestat was administered to the mice after the disease had established, on day 12 after immunization, there was a significant (~70%) decrease in the pathologic score of the disease compared with the group that was not administered the drug (Figs. 6B, 6C), indicating the therapeutic efficiency of AR inhibition.

We further measured T-cell viability in the presence of antigen hIRBP, without or with fidarestat, and observed that in the absence of AR inhibitor, the T cells proliferated approximately two-fold, whereas in the presence of inhibitor, their number did not increase significantly (data no shown). We further measured the levels of IL-17 in the T-cell media after antigen challenge. As shown in Figure 7, in the absence of hIRBP, the level of IL-17 increased significantly in the EAU-derived T-cell media compared with that of the control T cells, and T cells derived from fidarestat-treated mice showed significantly decreased IL-17 levels. However, when stimulated with the hIRBP, the EAU-derived T cells produced a significantly increased IL-17 in the culture media compared with control T cells. In T-cell medium from the fidarestat-treated EIU mice, the level of IL-17 was significantly lower than in the EAU-derived T-cell medium. Furthermore, when the T cells were stimulated with the hIRBP in the presence of the AR inhibitor, the EAU-
derived T cells still produced a significantly increased IL-17 in the culture medium, whereas in T-cell medium from the fidarestat-treated EIU mice, the level of IL-17 was significantly reduced compared with that in medium from the EAU-derived T cells.

**AR Deficiency in Mice Protects against the Acute Form of Uveitis**

After determining the role of AR in the chronic form of uveitis in mice, we examined the role of AR deficiency in the acute form of uveitis in ARKO mice. As shown in Figure 8A, the clinical score of the disease was 2.41 ± 0.64 in the WT mice at 24 hours after LPS injection, whereas in the ARKO mice, the clinical score decreased significantly (~50%) and was 0.98 ± 0.40.

Since the aqueous humor from the mouse eye is in miniscule amounts and is difficult to obtain, we used whole-eye lysate to determine the inflammatory markers in the eye. As shown in Table 2, the levels of inflammatory cytokines and chemokines increased significantly in the WT EIU mouse eye whereas in the ARKO EIU mice, their levels were markedly less.

We further examined the expression of other inflammatory markers in eye lysate such as TNF-α, iNOS, COX-2, and VCAM-1, which were found to be elevated several fold in eyes from the EIU WT mice, whereas their expression level was significantly less in the ARKO EIU mouse eye (Fig. 8B). The control mouse eye had basal levels of expression of these inflammatory proteins. We next examined the activation of signaling molecule PKC and transcription factor nuclear factor-κB (NF-κB), the key mediators of redox signals, in the whole-eye lysate. At 24 hours after the LPS injections, there was increased phosphorylation of PKC βII and NF-κB in the whole-eye lysate from the WT EIU mice, whereas in the ARKO EIU mouse eye lysates, phosphorylation was similar to the basal levels in the control mouse eye lysates (Fig. 8C). Taken together, these results thus suggest that deficiency of AR offers protection in acute form of exogenous uveitis which is caused mainly by infection.

**DISCUSSION**

In the present study, we have investigated the effect of AR deficiency and efficacy of the AR inhibitor fidarestat in chronic (EAU) and acute (EIU) models of mice immunized with hIRBP or injected with the bacterial endotoxin LPS. Our results show that whereas the WT mice exhibited a severe onset of disease at day 21 after hIRBP immunization or 24 hours after LPS injections, the ARKO mice showed significantly fewer symptoms associated with EAU or EIU pathogenesis. In both models of uveitis, the ARKO mice showed significant prevention of the disease.

We have demonstrated that pharmacologic inhibition of AR significantly prevents LPS-induced uveitis in rats by blocking the ROS–induced signaling that activates NF-κB. However, to confirm the involvement of AR in the pathogenesis of uveitis, we considered it necessary to use an AR-knockout experimental animal model, and since generating such model is not possible in rats, we used ARKO mice on the C57BL/6 background for our studies. These mice had mild impairment in water reabsorption in the kidney, leading to slightly increased urine output and increased water consumption, but had no phenotypic alteration in the eye.

The pathogenesis of EAU in mice presents an enormous similarity with the posterior uveitis in humans with autoimmune etiology. The immunization with a retinal peptide, such as hIRBP, with concurrent administration of PTX and CFA containing heat-killed tuberculosis bacteria triggers bacterial pattern recognition receptors on immune cells, such as monocytes, dendritic cells, neutrophils, natural killer (NK) cells, and T cells and provides the proinflammatory environment that activates the autopathogenic effector pathway leading to uveitis pathogenesis. This model of uveitis is not only similar to the human endogenous uveitis in terms of the clinical symptoms, but it also shares the basic pathogenic mechanisms. Similarly, the bacterial endotoxin-induced uveitis is used to investigate the mechanism and therapeutic intervention of anterior uveitis in humans. Further, the role of oxidative stress in the pathogenesis of uveitis has been recognized in both forms of the disease. Recently, investigators have identified mitochondrial oxidative stress in the photoreceptor layer during early EAU, which apparently resulted from

**Table 2. Expression of Inflammatory Markers in Culture Media from EIU Mouse-Derived T-Cells Injected with Lipopolysaccharide**

<table>
<thead>
<tr>
<th>Growth Factors, Cytokines, Chemokines</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WT-CTRL vs. ARKO CTRL</strong></td>
<td></td>
</tr>
<tr>
<td>VEGF, Fractalkine, GM-CSF, IFN-γ, Leptin, MCP-1, MIP-3α, β-NGF, TIMP-1, IL-1α, IL-1β, IL-6, IL-10, TNF-α, CINC-3, CNTF</td>
<td>0-1</td>
</tr>
<tr>
<td><strong>WT-EIU vs. WT-CTRL</strong></td>
<td></td>
</tr>
<tr>
<td>CINC-3, CNTF, Fractalkine, IL-6, MIP-3α, IFN-γ, IL-1α, IL-1β, IL-10, Leptin, GM-CSF, β-NGF, TNF-α, VEGF, MCP-1, LIX, TIMP-1</td>
<td>0-1, 1-3, 2-4, 2-5, 3-5</td>
</tr>
<tr>
<td><strong>WT-EIU vs. ARKO-EIU</strong></td>
<td></td>
</tr>
<tr>
<td>IL-4, IL-6, IL-10, CINC-3, Fractalkine, IL-1α, IL-1β, LIX, Leptin, CINC-2, CNTF, IL-1α, IL-1β, IFN-γ, MIP-3α, β-NGF, VEGF, TIMP-1, TNF-α, MCP-1</td>
<td>0-1, 1-2</td>
</tr>
</tbody>
</table>

AR deficiency prevented an LPS-induced increase in cytokines, chemokines, and growth factors in mouse eyes. A membrane-based cytokine antibody array system was used to determine the expression levels of the inflammatory factors in the T-cell media. The spots on the array membrane were analyzed by densitometry, and the data are presented as fold change. The WT-EIU and ARKO-EAU T-cell media served as controls (n = 4).
AR-Deficiency Protects against Uveitis

In the acute form of the disease by using an EIU model in mice. We injected LPS SC into mice, which caused severe inflammation in the eye, equivalent to a pathologic score more than 2.5 on a scale of 4 in the WT mice which was significantly less in the ARKO mice (≈1). Similarly, the levels of various cytokines and chemokines were markedly increased in the eyes of the WT EIU mice, whereas in the ARKO mice, the increase was markedly less. Further, expression of inflammatory marker proteins, such as iNOS, COX-2, TNF-α, and VCAM-1, was increased in the WT EIU mouse eyes, but there was no such increase in the ARKO mice. These results suggest that AR deficiency protects...
mice against the pathogenesis of both type of disease (i.e., infection-and autoimmune-induced).

We next tested the effect of AR inhibition and found that administration of fidarestat prevented the development of EIU in mice, as well as the secrction of IL-17 from the T cells isolated from the spleen. These results confirm our findings in the ARKO mice and suggest that AR inhibition could be a novel approach for therapeutic intervention in the management of autoimmune uveitis in humans.

The mechanistic details of how AR regulates the redox signaling are not clear yet. However, the evidence collected in our laboratory in the past decade indicates that oxidative stress generates large amount of lipid-derived aldehydes by peroxidation of membrane lipids, which readily conjugate with glutathione and are reduced to respective alcohols by AR. The reduced GS-lipid alcohols act as signaling intermediates and activate several protein kinases by a still uncertain mechanism, eventually activating redox-sensitive transcription factors and causing inflammation and further enhancing the prevailing oxidative stress and continuing cyclic episodes that lead to disease establishment and progression. Inhibition of AR blocks the production of GS-lipid alcohols which could halt this cycle and prevents disease progression.

References